| Literature DB >> 31344785 |
Dai-Hung Ngo1, Thanh Sang Vo2.
Abstract
Gamma-aminobutyric acid (Gaba) is a non-proteinogenic amino acid that is widely present in microorganisms, plants, and vertebrates. So far, Gaba is well known as a main inhibitory neurotransmitter in the central nervous system. Its physiological roles are related to the modulation of synaptic transmission, the promotion of neuronal development and relaxation, and the prevention of sleeplessness and depression. Besides, various pharmaceutical properties of Gaba on non-neuronal peripheral tissues and organs were also reported due to anti-hypertension, anti-diabetes, anti-cancer, antioxidant, anti-inflammation, anti-microbial, anti-allergy, hepato-protection, reno-protection, and intestinal protection. Therefore, Gaba may be considered as potential alternative therapeutics for prevention and treatment of various diseases. Accordingly, this updated review was mainly focused to describe the pharmaceutical properties of Gaba as well as emphasize its important role regarding human health.Entities:
Keywords: Gaba; Gaba-rich product; anti-hypertension; bioactivity; health benefit
Year: 2019 PMID: 31344785 PMCID: PMC6696076 DOI: 10.3390/molecules24152678
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Therapeutic targets for neuroprotective activity of Gaba.
Neuroprotective effect of Gaba.
| STT | Source | Dose, Model | Time of Treatment/Administration | Effect | Ref. |
|---|---|---|---|---|---|
| 1 | Kimchi-derived | 100 µg/mL, neuronal cells | 24 h | Preventing neurotoxic-induced cell death | [ |
| 2 | 537.23 mg/L, PC12 cells | 30 min | Preventing MnCl2-induced injury | [ | |
| 3 | Gaba receptor agonist | Muscimol (1 mg/kg) and baclofen (20 mg/kg), rat | 30 min | Preventing brain ischemic injury and decreasing apoptosis | [ |
| 4 | Gaba receptor agonist | Baclofen (10 mL/kg), rat | Once daily/five weeks | Alleviating neuronal damage and suppressing cytodestructive autophagy | [ |
Figure 2Preventive action of Gaba on neurological disorders.
Neurological disorder prevention of Gaba.
| STT | Source | Dose/Model | Time of Treatment/Administration | Effect | Ref. |
|---|---|---|---|---|---|
| 1 | Gaba-enriched rice germ | 26.4 mg/3 times/day, patient | N/A | Improving sleeplessness, somnipathy, and depression | [ |
| 2 | Gaba-rich Monascus-fermented product | 2.6 mg/kg, rat | 30 days | Preventing depression | [ |
| 3 | Gaba powder from natural fermentation using lactic acid bacteria | 100 mg Gaba/day, Japanese volunteers | 1 week | Prevention of sleep disorder | [ |
| 4 | Gaba (90.8%) and l-theanine (99.3%) was supplied by Neo Cremar Co. Ltd. (Seoul, Korea) and BTC Co. Ltd. (Ansan, Korea), respectively | Gaba/L-theanine mixture (100/20 mg/kg)/day, mice and rat | 9 days | Decreasing sleep latency and increasing sleep duration | [ |
| 5 | Gaba from natural fermentation using lactic acid bacteria (Pharma-GABA, Pharma Foods International Co., Japan) | Gaba/L-theanine mixture (100/200 mg/kg)/day Japanese volunteers | 7 days | Increasing relaxation, diminishing anxiety, and enhancing immunity | [ |
| 6 | Gaba-enriched product fermented by kimchi-derived lactic acid bacteria | 46.69 mg/mL Gaba, mice and PC-12 cells | 24 h | Improving long-term memory loss and increasing neuronal cell proliferation | [ |
| 7 | Gaba-enriched fermented | 1.5 g/day, volunteers | 6 weeks | Preventing cognitive impairment in the elderly | [ |
Anti-hypertensive effect of Gaba.
| STT | Source | Dose/Model | Time of Treatment/Administration | Effect | Ref. |
|---|---|---|---|---|---|
| 1 | Milk fermented by | 0.70 mg/ml | 5 min | Inhibiting 50% ACE activity | [ |
| 2 | Gaba form LAB-fermented soybean | 1.3 mg Gaba/g soybean | 10 min | Inhibiting 43% ACE activity | [ |
| 3 | Gaba from the fermented lentils | 10.42 mg Gaba/g extract | 60 min | Inhibiting 92% ACE activity | [ |
| 4 | Gaba from Wako Pure Chemicals (Tokyo) | 0.3 to 300 mg Gaba/kg, rat | Every 20 min for i.v. administration | Decreasing blood pressure | [ |
| 5 | Gaba from skim cows’ milk fermented with | 5 mL (102 mg Gaba/kg) of the fermented solution/kg body weight, rat | 10 h | Lowering blood pressure | [ |
| 6 | Gaba-enriched rice grains | 0.1 mg–0.5 mg Gaba/kg, rat | 6 weeks | Decreasing blood pressure | [ |
| 7 | Gaba-enriched white rice | 150 g of Gaba-enriched white rice (11.2 mg Gaba/100 g rice), volunteers | 8 weeks | Decreasing blood pressure | [ |
| 8 | Gaba-enriched Chingshey purple sweet potato-fermented milk by lactic acid bacteria | 2.5-mL dose of fermented-milk, rat | 8 weeks | Reducing both systolic blood pressure and diastolic blood pressure | [ |
| 9 | Gaba from probiotic-fermented purple sweet potato yogurt | 1500 µg/2.5 mL/kg, rat | 8 weeks | Alleviating cardiac hypertrophy | [ |
| 10 | Gaba-rich tomato | 2–10 g/kg, rat | 2–24 h | Decreasing blood pressure | [ |
| 11 | Gaba-rich bread | 120 g/day, patient | 3 days | Decreasing blood pressure | [ |
Figure 3Therapeutic targets for anti-diabetic activity of Gaba.
Anti-diabetic effect of Gaba.
| STT | Source | Dose/Model | Time of Treatment/Administration | Effect | Ref. |
|---|---|---|---|---|---|
| 1 | Gaba (Source: N/A) | Dose: N/A, mice | 8–15 weeks | Activating PI3-K/Akt-dependent growth and survival pathways and restoring the β-cell mass | [ |
| 2 | Gaba (MilliporeSigma, Burlington, MA, USA) | Gaba (6 mg/mL/day), mice | 10 weeks | Up-regulating β-cell proliferation and rising a distinct subpopulation of β cells | [ |
| 3 | Gaba (Sigma, St. Louis, USA) | Gaba (2 mg/mL/day), mice | 20 weeks | Reducing the concentrations of fasting blood glucose, improving glucose tolerance and insulin sensitivity, and inhibiting the body weight gain | [ |
| 4 | Gaba from pre-germinated brown rice | Pre-germinated brown rice (1387–1546 g/day), rat | 7 weeks | Decreasing blood glucose, adipocytokine PAI-1 concentration, and plasma lipid peroxide | [ |
| 5 | Gaba from germinated brown rice | Gaba (200 mg/kg/day), rat offspring | 8 weeks | Increasing adiponectin levels and reducing insulin resistance and oxidative stress | [ |
| 6 | Gaba from blackish purple pigmented rice with a giant embryo | Diet supplemented with either 20% ( | 8 weeks | Decreasing blood glucose and plasma insulin levels, adipokine concentrations, and hepatic glucose-regulating enzyme activities | [ |
| 7 | Gaba-enriched wheat bran | 15% Gaba-enriched bran, rat | 8 weeks | Improving glucose homeostasis | [ |
| 8 | Gaba from pre-germinated brown rice | The test sample contained 50 g of available carbohydrate per day for each volunteer (185 g of pre-germinated brown rice), volunteers | 7 weeks | Lowering postprandial blood glucose concentration without insulin secretion increase | [ |
| 9 | Gaba from pre-germinated brown rice | 180 g of the cooked rice/three times per day, patient | 14 weeks | Decreasing blood glucose and hypercholesterolemia | [ |
| 10 | Fermented tea product | 50 mg/kg, rat | 120 min | Decreasing blood glucose level | [ |
| 11 | Mung bean fermented by | 200 mg/kg and 1000 mg/kg, mice | 240 min | Reducing blood glucose, HbA1c, cholesterol, triglyceride, and low-density lipoprotein levels | [ |
| 12 | Yogurt fermented by | Gaba orally at a dose of 2 g/L or 4 g/L | 6 weeks | Reducing blood glucose, HbA1c, cholesterol, triglyceride, and low-density lipoprotein levels | [ |
| 13 | Soybean extract fermented by | 500 mg/kg, mice | 8 weeks | Reducing blood glucose, HbA1c, cholesterol, triglyceride, and low-density lipoprotein levels | [ |
| 14 | Milk fermented by strain YF-L812 ( | Fermented milk 0.2% and 0.6%/kg/day, mice | 6 weeks | Decreasing fasting blood glucose, serum insulin, insulin tolerance, total cholesterol, triglycerides, and LDL cholesterol | [ |
Anti-cancer effect of Gaba.
| STT | Source | Dose/Model | Time of Treatment/Administration | Effect | Ref. |
|---|---|---|---|---|---|
| 1 | Gaba-enriched brown rice extract | 20 µL extract/well (1 × 105 cells/200 mL/well), leukemia cells and HeLa cells | 48 h | Retarding the proliferation rates of leukemia cells and enhancing apoptosis of leukemia cells | [ |
| 2 | Gaba from Sigma Company (St. Louis, MO, USA) | Gaba (1–1000 µmol/L), cholangiocarcinoma QBC939 cells | 24 h | Inhibiting the activity and expression of MMP-2 and MMP-9 | [ |
| 3 | Gaba was purchased from Sigma-Aldrich, Shanghai, China | Gaba (100 µM), Colon cancer cells | 72 h | Inhibiting on cell proliferation and metastasis | [ |
| 4 | Gaba from Sigma Company (St. Louis, MO, USA) | Gaba (1000 mg/kg), rat | 25 weeks | Decreasing the number of gastric cancers of the glandular stomach | [ |
| 5 | Gaba from Sigma Company (St. Louis, MO, USA) | Gaba (10 µM), Human liver cancer cells | 24 h | Reducing intrahepatic liver metastasis and inhibiting human liver cancer cell migration and invasion | [ |
Figure 4Modulatory activity of Gaba for antioxidant promotion.
Figure 5Therapeutic targets for anti-inflammatory activity of Gaba.
Figure 6Therapeutic targets for anti-allergic activity of Gaba.
Figure 7Mechanism of the action of Gaba for hepatoprotection.
Figure 8Mechanism of the action of Gaba for renoprotection.